Zai Lab li­cens­es pso­ri­a­sis drug from Crescen­do; Hit­Gen, Li­on raise cash for dis­cov­ery and de­vel­op­ment work in Asia

→ Shang­hai’s Zai Lab has inked an ex­clu­sive li­cens­ing deal with Crescen­do Bi­o­log­ics un­der which Zai Lab will de­vel­op, com­mer­cial­ize, and man­u­fac­ture a top­i­cal an­ti­body VH do­main ther­a­peu­tic for in­flam­ma­to­ry ap­pli­ca­tions. Crescen­do’s prod­uct can­di­date was de­vel­oped us­ing the com­pa­ny’s trans­genic plat­form, which makes nov­el small pro­tein drugs based on ful­ly hu­man VH do­main build­ing blocks. Zai Lab plans to file an IND for the drug’s clin­i­cal stud­ies in pso­ri­a­sis in 2019, ac­cord­ing to a com­pa­ny state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER